# Long Term Extension Study in Patients With Primary Hyperoxaluria

> **NCT04042402** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 75 (estimated)

## Conditions studied

- Primary Hyperoxaluria Type 1 (PH1)
- Primary Hyperoxaluria Type 2 (PH2)
- Kidney Diseases
- Urologic Diseases
- Genetic Disease
- Primary Hyperoxaluria Type 3 (PH3)

## Interventions

- **DRUG:** DCR-PHXC

## Key facts

- **NCT ID:** NCT04042402
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-09
- **Primary completion:** 2030-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04042402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04042402, "Long Term Extension Study in Patients With Primary Hyperoxaluria". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04042402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*